20 results on '"Resmini, G"'
Search Results
2. OBSERVATIONAL ITALIAN STUDY ON SEVERE OSTEOPOROSIS (ISSO): EVALUATION OF BASELINE CHARACTERISTICS AND QUALITY OF LIFE IN POSTMENOPAUSAL FEMALES AND MALES
- Author
-
Adami S, Maugeri D, Toscano V, Topa G, Caminiti M, Brancati AM, Massarotti MS, Osella G, Malavolta N, Cagnoni C, Camozzi V, Parravicini L, Nardi A, Migliaccio S, Ulivieri FM, Resmini G, Silvestri S, Tauchmanova L., IOLASCON, Giovanni, Adami, S, Maugeri, D, Toscano, V, Topa, G, Caminiti, M, Brancati, Am, Massarotti, M, Osella, G, Malavolta, N, Iolascon, Giovanni, Cagnoni, C, Camozzi, V, Parravicini, L, Nardi, A, Migliaccio, S, Ulivieri, Fm, Resmini, G, Silvestri, S, and Tauchmanova, L.
- Published
- 2010
3. Evaluation of BMD Changes in Women with Severe Osteoporosis after Teriparatide Treatment
- Author
-
Malavolta N, Buffa A, Vukatana G, Mule R, Frigato M, Migliaccio S, Resmini G, Borghi C., IOLASCON, Giovanni, Malavolta, N, Buffa, A, Vukatana, G, Mule, R, Frigato, M, Migliaccio, S, Iolascon, Giovanni, Resmini, G, and Borghi, C.
- Published
- 2008
4. Bone microarchitecture of the hip in osteoporosis and osteoarthritis
- Author
-
Carbonare LD, Resmini G, Redaelli C, Bertoldo F, Valenti MT, Migliaccio S, Giannini S, Maggi S, Sala U, Crepaldi G, Lo Cascio V., IOLASCON, Giovanni, Carbonare, Ld, Resmini, G, Redaelli, C, Bertoldo, F, Valenti, Mt, Migliaccio, S, Iolascon, Giovanni, Giannini, S, Maggi, S, Sala, U, Crepaldi, G, and Lo Cascio, V.
- Published
- 2006
5. Bone quality in hip fractures and hip osteoarthritis
- Author
-
Resmini G, Redaelli C, Sala U, Carbonare LD, Migliaccio S, Brama M, Maggi S, Noale M, Malavolta N, Gandolini G, Bevilacqua M, Lello S, Crepaldi G., IOLASCON, Giovanni, Resmini, G, Redaelli, C, Sala, U, Carbonare, Ld, Migliaccio, S, Brama, M, Maggi, S, Noale, M, Iolascon, Giovanni, Malavolta, N, Gandolini, G, Bevilacqua, M, Lello, S, and Crepaldi, G.
- Published
- 2006
6. Safety and compliance of teriparatide treatment in postmenopausal women with osteoporosis: Comparison between clinical trials and an Italian observational multicentric clinical practice
- Author
-
Malavolta N, Migliaccio S, Gandolini G, Frigato M, Bevilacqua M, Maggi S, Falcone S, Lello S, Mule R, Sala U, Spera G, Dalle Carbonare L, Guarcello G, Crepaldi G, Resmini G., IOLASCON, Giovanni, Malavolta, N, Migliaccio, S, Gandolini, G, Frigato, M, Bevilacqua, M, Maggi, S, Falcone, S, Lello, S, Mule, R, Sala, U, Iolascon, Giovanni, Spera, G, Dalle Carbonare, L, Guarcello, G, Crepaldi, G, and Resmini, G.
- Published
- 2006
7. Evaluation of adherence and persistence to teriparatide treatment in patients affected by severe osteoporosis: a multicentre observational real life study
- Author
-
Migliaccio, Silvia, Resmini, G., Buffa, A., Fornari, Rachele, Di Pietro, G., Parocchi, E., Dormi, A., Gimigliano, F., Mule, R., Celi, M., Frigato, M., Lenzi, Andrea, Tarantino, U., Iolascon, G., and Malavolta, N.
- Published
- 2011
8. Effectiveness of teriparatide treatment on back pain-related functional limitations in individuals affected by severe osteoporosis: A prospective pilot study
- Author
-
Iolascon, G., Gimigliano, F., Malavolta, N., Tarantino, U., Fornari, R., Greco, E., Di Pietro, G., Gimigliano, R., Andrea Lenzi, Resmini, G., Migliaccio, S., Iolascon, Giovanni, Gimigliano, Francesca, Malavolta, N, Tarantino, U, Fornari, R, Greco, E, Di Pietro, G, Gimigliano, Raffaele, Lenzi, A, Resmini, G, and Migliaccio, S.
- Subjects
teriparatide ,health-related quality of life ,back-pain ,Original Article ,osteoporosi ,functional limitation ,osteoporosis - Abstract
INTRODUCTION: Vertebral fractures have been associated with back pain, functional limitations and reduced health-related quality of life (HRQoL). Teriparatide is the first effective anabolic agent that demonstrated to significantly reduce the risk of vertebral fracture by 65%, as compared to placebo. The aims of this study were to evaluate the effectiveness of teriparatide treatment on back pain-related functional limitations and to investigate on patients HRQoL. MATERIALS AND METHODS: In this prospective observational pilot study osteoporotic patients, who were prescribed teriparatide therapy and a supplementation of calcium and vitamin D, were asked to answer to two self-administered questionnaires: the Spine Pain Index (SPI) and the SF-12 (at the recruitment, after 6, 12, and 18 months). RESULTS: Fifty-two women were evaluated (mean age of 70.58 yrs). The mean SPI score passed from 50.01 at baseline to 32.20 at 18 months. The mean SF-12 PCS score passed from 30.00 at baseline to 36.79 at 18 months, while the mean SF-12 MCS score was already within the normality range at baseline, constantly improving during the 18 months. CONCLUSION: In conclusion, 18 months of treatment with teriparatide has to be considered an effective therapeutic option for women with severe osteoporosis and vertebral fractures, in a real-life clinical setting, to improve both back pain related disability and quality of life.
9. 79-year-old post-menopausal woman with humerus fracture during teriparatide treatment
- Author
-
Resmini, G., Giovanni Iolascon, Resmini, G, and Iolascon, Giovanni
- Subjects
Fracture Healing ,Radiography ,Humeral Fractures ,Fractures, Spontaneous ,Bone Density Conservation Agents ,Teriparatide ,Humans ,Female ,Osteoporosis, Postmenopausal ,Thoracic Vertebrae ,Aged - Abstract
The patient, a 79-year-old woman with a history of osteoporosis, presented with acute back pain without trauma, three years ago. Spinal X rays showed a vertebral compression fracture at T7, and DXA indicated a T-score of -2.65 BMD at the total hip. The patient started treatment with alendronate 70 mg once a week, plus calcium and vitamin D supplementation. After two years, she presented new acute back pain, and spinal X-rays revealed new vertebral compression fractures at T8 and T11. In September 2004, she stopped alendronate therapy and began teriparatide 20 microg subcutaneously each day for 18 months, associated with a dose of 1200 mg/day of calcium and 880 IU/day of vitamin D. In July 2005, she fell and sustained a fracture of the left proximal humerus. She was treated with conservative therapy and continued teriparatide therapy. After 25 days of conservative management, left shoulder X-ray showed quick formation of fracture healing. In conclusion, although teriparatide is indicated for the treatment of severe osteoporosis and not to enhance fracture healing, there are many experimental data which indicate that it may be beneficial also in enhancing fracture healing. The patient, a 79-year-old woman with a history of osteoporosis, presented with acute back pain without trauma, three years ago. Spinal X rays showed a vertebral compression fracture at T7, and DXA indicated a T-score of -2.65 BMD at the total hip. The patient started treatment with alendronate 70 mg once a week, plus calcium and vitamin D supplementation. After two years, she presented new acute back pain, and spinal X-rays revealed new vertebral compression fractures at T8 and T11. In September 2004, she stopped alendronate therapy and began teriparatide 20 microg subcutaneously each day for 18 months, associated with a dose of 1200 mg/day of calcium and 880 IU/day of vitamin D. In July 2005, she fell and sustained a fracture of the left proximal humerus. She was treated with conservative therapy and continued teriparatide therapy. After 25 days of conservative management, left shoulder X-ray showed quick formation of fracture healing. In conclusion, although teriparatide is indicated for the treatment of severe osteoporosis and not to enhance fracture healing, there are many experimental data which indicate that it may be beneficial also in enhancing fracture healing.
10. Inhibition of RANK ligand: A new option for preventing fragility fractures
- Author
-
Giovanni Iolascon, Resmini G, Tarantino U, Iolascon, Giovanni, Resmini, G, and Tarantino, U.
- Subjects
musculoskeletal diseases ,Clinical Trials as Topic ,RANK Ligand ,Osteoclasts ,Biological ,Bone and Bones ,Treatment Outcome ,Bone Resorption ,Humans ,Fractures, Bone ,Models, Biological ,Models ,Settore MED/33 - Malattie Apparato Locomotore ,Bone ,Fractures - Abstract
Cortical and trabecular bone undergo a continuous and balanced remodeling process, consisting of an osteoclast-mediated bone-resorption phase and an osteoblast-mediated bone-formation phase. An imbalance in this process, which favours bone resorption, results in bone loss and in damage to the skeletal microarchitecture. A new targeted anti-resorptive approach is represented by the inhibition of RANK ligand (RANKL), which is one of the primary mediators of osteoclast activity, essential for osteoclast formation, function and survival. (Aging Clin Exp Res 2011; 23 (Suppl. to No. 2): 28-29) (C) 2011, Editrice Kurtis
11. New insights into the role of teriparatide
- Author
-
Resmini G, Giovanni Iolascon, Resmini, G, and Iolascon, Giovanni
- Abstract
Parathyroid hormone (PTH) is secreted by the parathyroid glands and is an important regulator of blood calcium concentrations. Synthesis and secretion of PTH are stimulated by a decrease in blood calcium. PTH has three actions: 1) to increase the release of calcium from bone, 2) to reduce renal clearance of calcium, and 3) to stimulate the production of 1,25 (OH)(2)D(3). Human parathyroid hormone is a single chain polypeptide with 84 amino acids and a molecular weight of 9425 Da. The N-terminal region, 1-34, is biologically active and sufficient for regulation of mineral ion homeostasis (1). Recombinant teriparatide {human PTH(1-34) [hPTH (1-34)]}, currently the only bone-forming osteoporosis drug available for clinical use, increases bone turnover with a greater stimulation of formation than resorption (2). Bone turnover markers also rise during treatment with teriparatide (TPTD), with markers of bone formation rising early and rapidly, followed by rises in bone resorption markers. (Aging Clin Exp Res 2011; 23 (Suppl. to No. 2): 30-32) (C) 2011, Editrice Kurtis
12. Osteocalcin production in vivo and in vitro after 1,25-dihydroxycholecalciferol stimulation comparison of different assays
- Author
-
Villa, I., Giuseppe Banfi, Daverio, R., Resmini, G., Rubinacci, A., I., Villa, Banfi, Giuseppe, R., Daverio, G., Resmini, and A., Rubinacci
- Subjects
Osteocalcin ,Radioimmunoassay ,Immunoenzyme Technique ,Reagent Kit ,Sensitivity and Specificity ,Immunoenzyme Techniques ,Calcitriol ,Humans ,Female ,Reagent Kits, Diagnostic ,Diagnostic ,Human ,Aged - Abstract
The study was designed to assess the sensitivity of three commercial assays (which differ in methodology, standard and antibodies) for osteocalcin, used for detecting changes in osteocalcin secretion induced by calcitriol (1,25-dihydroxycholecalciferol) in vivo and in vitro. Osteocalcin levels were determined in serum samples of 10 osteoporotic women after short term calcitriol treatment, and in the culture medium of human osteoblast-like cells (n = 22) after 48 h calcitriol exposure. All assays displayed similar sensitivity in detecting osteocalcin production in vivo after a 1 microgram daily dose of calcitriol. A novel IRMA (CIS), claimed to detect intact osteocalcin, showed higher osteocalcin values than the other assays, and in vitro showed the best sensitivity; it provides an appropriate index of the osteocalcin synthetic activity of cultured human osteoblasts.
13. The Italian observational study on severe osteoporosis (ISSO): 24-month results on incidence of fractures and adherence to treatment
- Author
-
Idolazzi, L., Maugeri, D., Monti, S., Massarotti, M., Osella, G., Barbagallo, M., Del Fiacco, R., Silvestri, S., Adami, S., Altomonte, L., Bardoscia, A., Bertoldo, F., Bevilacqua, M., Bianchi, G., Brancati, A., Cagnoni, C., Cantatore, F. P., Capone, A., Costanzo, G., D Avola, G., Giorgi, G., Di Matteo, L., Di Munno, O., Filipponi, P., Frisina, N., Fusco, A., Giannini, S., Guiducci, S., Iolascon, G., Isaia, G., Lombardi, G., Malavolta, N., Marcocci, C., Migliaccio, S., Migliore, A., Muratore, M., Nardi, A., Ortolani, S., Pasquali, R., Petto, H., Pietrogrande, L., Pola, E., Previti, B., Resmini, G., Alessandro Rubinacci, Russo, E., Scillitani, A., Silveri, F., Leali, P. T., Trotta, F., Ulivieri, M., Verdoia, C., Versace, F., Vinicola, V., Idolazzi, Luca, Maugeri, Domenico, Monti, Salvatore, Massarotti, Marco, Osella, Giangiacomo, Barbagallo, Mario, Del Fiacco, Romano, Silvestri, Sandra, Adami, Silvano, Altomonte, Lorenzo, Bardoscia, Alfredo, Bertoldo, Francesco, Bevilacqua, Maurizio, Bianchi, Gerolamo, Brancati, Annamaria, Cagnoni, Carlo, Cantatore, Francesco Paolo, Capone, Antonio, Costanzo, Giuseppe, D'Avola, Giovanni, De Giorgi, Giuseppe, Di Matteo, Luigi, Di Munno, Ombretta, Filipponi, Paolo, Frisina, Nicola, Fusco, Alessandra, Giannini, Sandro, Guiducci, Serena, Iolascon, Giovanni, Isaia, Giancarlo, Lombardi, Gaetano, Malavolta, Nazzarena, Marcocci, Claudio, Migliaccio, Silvia, Migliore, Alberto, Muratore, Maurizio, Nardi, Alfredo, Ortolani, Sergio, Pasquali, Renato, Petto, Helmut, Pietrogrande, Luca, Pola, Enrico, Previti, Baldassarre, Resmini, Giuseppina, Rubinacci, Alessandro, Russo, Enzo, Scillitani, Alfredo, Silveri, Ferdinando, Leali, Paolo Tranquilli, Trotta, Francesco, Ulivieri, Massimo, Verdoia, Cesare, Versace, Francesco, and Vinicola, Vincenzo
- Subjects
Spinal fracture ,Fracture ,Rheumatology ,Observational study ,Osteoporosis therapy ,Teriparatide ,Immunology ,Osteoporosi ,Immunology and Allergy ,Parathyroid hormone ,Spine - Abstract
Objective To estimate the proportion of patients with very severe osteoporosis (those covered by the reimbursement criteria of the Italian National Health Service) experiencing new vertebral and non-vertebral fragility fractures in the first 24 months of a new anti-osteoporosis treatment. Methods Prospective observational study in men and post-menopausal women (aged > 21 years) initiating anti-osteoporosis treatment for very severe osteoporosis. Eligibility was based on teriparatide (TPD) reimbursement criteria in Italy: Incident of vertebral or hip fracture during anti-resorptive treatment (minimum 1 year), or at least three prevalent severe vertebral fractures, or two prevalent severe vertebral fractures and a historical proximal hip fracture. Incidence of new clinical vertebral and non-vertebral fractures was documented by original x-rays and/or radiological reports, and a post-hoc analysis compared data from the TPD monotherapy population versus the total treated group. Results Overall, 767 patients (mean age 72.8 years, 90.7% women) were enrolled in the study, of whom 628, 538, 419 and 424 attended visits at 6, 12, 18 and 24 months, respectively. The most commonly prescribed therapy was TPD (single-agent; 64.5%), then bisphosphonates and other anti-resorptives (33.3%). A combination of different oral treatments was given to 22.5% of the patients. Overall treatment adherence at 24 months was 65.7%. In a post-hoc analysis, the overall incidence of new clinical vertebral and non-vertebral fractures in the total treated population was, respectively, 4.7% and 2.3% in the first 6 months; 1.8% and 1.6% in the 6-12 month period; 2.9% and 1.4% in the 12-18 month period; and 2.2% and 1.0% in the 18-24 month period. Conclusion In patients with very severe osteoporosis, the risk of new vertebral and non-vertebral fractures declined after the first 6 months and remained low throughout the study.
14. Are Dietary Supplements and Nutraceuticals Effective for Musculoskeletal Health and Cognitive Function? A Scoping Review
- Author
-
Alberto Migliore, Umberto Tarantino, Nicola Napoli, Nazzarena Malavolta, Silvia Migliaccio, Francesca Gimigliano, Andrea Giusti, Prisco Piscitelli, Giovanni Iolascon, Antimo Moretti, Massimiliano Bianco, Giuseppina Resmini, A. de Sire, Raffaele Gimigliano, Iolascon, Giovanni, Gimigliano, Raffaele, Bianco, M., de Sire, A., Moretti, A., Giusti, A., Malavolta, N., Migliaccio, S., Migliore, A., Napoli, N., Piscitelli, P., Resmini, G., Tarantino, U., and Gimigliano, Francesca
- Subjects
0301 basic medicine ,Gerontology ,medicine.medical_treatment ,Medicine (miscellaneous) ,law.invention ,chemistry.chemical_compound ,Dietary supplement ,Fluorides ,0302 clinical medicine ,Cognition ,Randomized controlled trial ,law ,Dietary supplements ,aging ,cognitive function ,musculoskeletal ,nutraceuticals ,Settore MED/33 - Malattie Apparato Locomotore ,Medicine ,Magnesium ,Micronutrients ,Musculoskeletal Diseases ,Amino Acids ,Vitamin D ,Nutrition and Dietetics ,Vitamin K2 ,Micronutrient ,Zinc ,Italy ,Vitamin B Complex ,nutraceutical ,Vitamin ,medicine.medical_specialty ,030209 endocrinology & metabolism ,Bone and Bones ,03 medical and health sciences ,Nutraceutical ,Fatty Acids, Omega-3 ,Vitamin D and neurology ,Humans ,Vitamin B12 ,Muscle, Skeletal ,Aged ,030109 nutrition & dietetics ,business.industry ,Vitamin E ,Calcium, Dietary ,chemistry ,Dietary Supplements ,Physical therapy ,Potassium ,Geriatrics and Gerontology ,business ,Cognition Disorders - Abstract
Objective: The aim of our scoping review was to summarize the state of the art regarding micronutrients in order to identify which of them might effectively improve health status in the areas typically impaired in older people: bone, skeletal muscle, and cognitive function. Design: Scoping review. Methods: The Italian Study Group on Healthy Aging by Nutraceuticals and Dietary Supplements (HANDS) performed this scoping review, based on the following steps: doing a list of micronutrients related with musculoskeletal or cognitive functions, included in dietary supplements and nutraceuticals commercialized in Italy; planning a research on PubMed, according to an evidence-based approach, in order to the most relevant positive study for each micronutrient into each of the three areas involved (bone, skeletal muscle and cognitive function); identifying the micronutrients effective in maintaining or achieving an adequate health status in older people, specifying the effective and safe daily doses, according to the selected studies. Results: In literature we found 12 relevant positive studies (1 international society guidelines/recommendations, 1 systematic review, 7 randomized controlled trials, and 3 prospective cohort studies). We showed that only 16 micronutrients resulted to have appropriate scientific evidences in terms of improving musculoskeletal health and/or cognitive function in older people: beta-alanine, calcium, creatine, fluorides, leucine, magnesium, omega-3 fatty acids, potassium, vitamin B6, vitamin B9, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K2, and zinc. Conclusion: This scoping review showed that selected micronutrients in adequate doses might have an ancillary role in musculoskeletal health and cognitive functions in older people. Objective: The aim of our scoping review was to summarize the state of the art regarding micronutrients in order to identify which of them might effectively improve health status in the areas typically impaired in older people: bone, skeletal muscle, and cognitive function. Design: Scoping review. Methods: The Italian Study Group on Healthy Aging by Nutraceuticals and Dietary Supplements (HANDS) performed this scoping review, based on the following steps: doing a list of micronutrients related with musculoskeletal or cognitive functions, included in dietary supplements and nutraceuticals commercialized in Italy; planning a research on PubMed, according to an evidence-based approach, in order to the most relevant positive study for each micronutrient into each of the three areas involved (bone, skeletal muscle and cognitive function); identifying the micronutrients effective in maintaining or achieving an adequate health status in older people, specifying the effective and safe daily doses, according to the selected studies. Results: In literature we found 12 relevant positive studies (1 international society guidelines/recommendations, 1 systematic review, 7 randomized controlled trials, and 3 prospective cohort studies). We showed that only 16 micronutrients resulted to have appropriate scientific evidences in terms of improving musculoskeletal health and/or cognitive function in older people: beta-alanine, calcium, creatine, fluorides, leucine, magnesium, omega-3 fatty acids, potassium, vitamin B6, vitamin B9, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K2, and zinc. Conclusion: This scoping review showed that selected micronutrients in adequate doses might have an ancillary role in musculoskeletal health and cognitive functions in older people.
- Published
- 2017
15. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy
- Author
-
Silvia Migliaccio, Rachele Fornari, Francesca Gimigliano, Giovanni Iolascon, Emanuela A. Greco, G. Di Pietro, S. Corvaglia, Giuseppina Resmini, Chiara Marocco, Nazzarena Malavolta, Davide Francomano, Elisabetta Romagnoli, Antimo Moretti, Andrea Lenzi, A. Buffa, A. de Sire, Migliaccio, S, Francomano, D., Romagnoli, E., Marocco, C., Fornari, R., Resmini, G., Buffa, A., Di Pietro, G., Corvaglia, S., Gimigliano, Francesca, Moretti, A., de Sire, A., Malavolta, N., Lenzi, A., Greco, E. A., and Iolascon, Giovanni
- Subjects
medicine.medical_specialty ,Pediatrics ,Bone density ,Endocrinology, Diabetes and Metabolism ,Osteoporosis ,030209 endocrinology & metabolism ,Medication Adherence ,Persistence ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Bone Density ,Observational study ,medicine ,Humans ,030212 general & internal medicine ,Medical prescription ,Osteoporosis, Postmenopausal ,Femoral neck ,Aged ,Bone Density Conservation Agents ,business.industry ,Therapeutic effect ,Osteoporosi ,Middle Aged ,medicine.disease ,Prognosis ,medicine.anatomical_structure ,Denosumab ,Fracture ,Italy ,Physical therapy ,Female ,business ,Body mass index ,Osteoporotic Fractures ,medicine.drug ,Follow-Up Studies - Abstract
Background: Persistence is commonly considered a key factor for the successful management of osteoporosis and fragility fractures. Denosumab is the first biologic agent developed for the treatment of osteoporosis with satisfying data regarding the persistence with this therapy. Aim: The purpose of this multicenter observational real practice study was to evaluate the persistence with denosumab treatment in post-menopausal women affected by osteoporosis. Material/subjects and methods: Women were recruited in four specialized centers for the management of osteoporosis in North, Center and South of Italy. We included women with a diagnosis of post-menopausal osteoporosis, aged >50 years, able to obtain a prescription according to the Italian reimbursement criteria in force during the study period for anti-osteoporotic pharmacological treatment. They initiated a treatment with subcutaneous denosumab (Prolia ® ) 60 mg/every 6 months between November 2011 and May 2016. Women who had received aromatase inhibitors were excluded. Patients were assessed at baseline and every 6 months for all treatment length. Persistence data were evaluated for a total of 36 months. Results: Eight hundred seventy women were enrolled; mean aged 70 years, with a mean body mass index of 24.8 ± 4.1 kg/m 2 . At the Dual-energy X-ray absorptiometry assessment, the mean lumbar spine T-score was −2.76 ± 1.14 standard deviations (SD) and the mean femoral neck T-score was −2.49 ± 0.80 SD. During the study, the total persistence was 91.4%. Total dropouts were 75 (8.6%), higher within the initial 6-month period of treatment. Conclusions: Persistence to denosumab treatment in our observational real practice study was very high. These results suggest that factors such as frequency of visits, pharmacological schedule, and opportunity to call the doctor might play an important role in the persistence and adherence to treatment to obtain maximum therapeutic effect and avoid further fragility fractures. Background: Persistence is commonly considered a key factor for the successful management of osteoporosis and fragility fractures. Denosumab is the first biologic agent developed for the treatment of osteoporosis with satisfying data regarding the persistence with this therapy. Aim: The purpose of this multicenter observational real practice study was to evaluate the persistence with denosumab treatment in post-menopausal women affected by osteoporosis. Material/subjects and methods: Women were recruited in four specialized centers for the management of osteoporosis in North, Center and South of Italy. We included women with a diagnosis of post-menopausal osteoporosis, aged >50 years, able to obtain a prescription according to the Italian reimbursement criteria in force during the study period for anti-osteoporotic pharmacological treatment. They initiated a treatment with subcutaneous denosumab (Prolia®) 60 mg/every 6 months between November 2011 and May 2016. Women who had received aromatase inhibitors were excluded. Patients were assessed at baseline and every 6 months for all treatment length. Persistence data were evaluated for a total of 36 months. Results: Eight hundred seventy women were enrolled; mean aged 70 years, with a mean body mass index of 24.8 ± 4.1 kg/m2. At the Dual-energy X-ray absorptiometry assessment, the mean lumbar spine T-score was −2.76 ± 1.14 standard deviations (SD) and the mean femoral neck T-score was −2.49 ± 0.80 SD. During the study, the total persistence was 91.4%. Total dropouts were 75 (8.6%), higher within the initial 6-month period of treatment. Conclusions: Persistence to denosumab treatment in our observational real practice study was very high. These results suggest that factors such as frequency of visits, pharmacological schedule, and opportunity to call the doctor might play an important role in the persistence and adherence to treatment to obtain maximum therapeutic effect and avoid further fragility fractures.
- Published
- 2017
16. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab
- Author
-
Maurizio Feola, Giuseppina Resmini, Umberto Tarantino, Giovanni Iolascon, Monica Celi, Federico Maria Liuni, Tarantino, U, Celi, M, Feola, M, Liuni, Fm, Resmini, G, and Iolascon, Giovanni
- Subjects
Male ,Oncology ,Aging ,medicine.medical_specialty ,Bone density ,Osteoporosis ,Osteoclasts ,Bone healing ,Antibodies, Monoclonal, Humanized ,Bone and Bones ,Bone resorption ,Fractures, Bone ,Mice ,Osteoprotegerin ,Bone Density ,Osteoclast ,Internal medicine ,medicine ,Animals ,Humans ,Bone Resorption ,Osteoporosis, Postmenopausal ,Cell Proliferation ,Randomized Controlled Trials as Topic ,Fracture Healing ,Bone Density Conservation Agents ,business.industry ,RANK Ligand ,Osteoporosi ,Fragility fracture ,medicine.disease ,Surgery ,Postmenopause ,Treatment Outcome ,Denosumab ,medicine.anatomical_structure ,Female ,Geriatrics and Gerontology ,business ,medicine.drug - Abstract
An imbalance of the remodeling process for bone resorption leads to a loss of tissue with consequent microarchitectural damage, evident in conditions such as osteoporosis and related fragility fractures. Currently, pharmacological therapies are able to prevent or slow down bone resorption by inhibiting osteoclast activity. An innovative and targeted anti-resorptive approach is represented by the inhibition of RANK ligand (RANK-L), essential for the proliferation and activity of osteoclastic cells. The human monoclonal antibody against RANK-L (denosumab) has been approved for the treatment of osteoporosis. In clinical trials of patients with osteoporosis, inhibition of RANK-L has reduced bone loss and damage to the microarchitecture and was associated with an increase in mass and resistance at different skeletal sites, with most significant effects than those demonstrated by any other antiresorptive drugs. In addition, after 3 years of treatment, it showed a reduction in vertebral and non-vertebral fracture risk. Denosumab treatment also has not revealed any alteration in the physiological processes of fracture repair, showing no increase in the onset of complications 3 years after the fracture. The data show that denosumab offers an effective alternative therapeutic approach for the treatment of severe osteoporosis, with positive effects on BMD and reduction of fragility fractures risk. So, promising results in terms of therapeutic efficacy and reliability make desirable the wide clinical use of denosumab for the treatment of osteoporotic fractures in the near future. © 2013 Springer International Publishing Switzerland. An imbalance of the remodeling process for bone resorption leads to a loss of tissue with consequent microarchitectural damage, evident in conditions such as osteoporosis and related fragility fractures. Currently, pharmacological therapies are able to prevent or slow down bone resorption by inhibiting osteoclast activity. An innovative and targeted anti-resorptive approach is represented by the inhibition of RANK ligand (RANK-L), essential for the proliferation and activity of osteoclastic cells. The human monoclonal antibody against RANK-L (denosumab) has been approved for the treatment of osteoporosis. In clinical trials of patients with osteoporosis, inhibition of RANK-L has reduced bone loss and damage to the microarchitecture and was associated with an increase in mass and resistance at different skeletal sites, with most significant effects than those demonstrated by any other antiresorptive drugs. In addition, after 3 years of treatment, it showed a reduction in vertebral and non-vertebral fracture risk. Denosumab treatment also has not revealed any alteration in the physiological processes of fracture repair, showing no increase in the onset of complications 3 years after the fracture. The data show that denosumab offers an effective alternative therapeutic approach for the treatment of severe osteoporosis, with positive effects on BMD and reduction of fragility fractures risk. So, promising results in terms of therapeutic efficacy and reliability make desirable the wide clinical use of denosumab for the treatment of osteoporotic fractures in the near future. © 2013 Springer International Publishing Switzerland.
- Published
- 2013
- Full Text
- View/download PDF
17. Mechanobiology of bone
- Author
-
Giuseppina Resmini, Umberto Tarantino, Giovanni Iolascon, Iolascon, Giovanni, Resmini, G, and Tarantino, U.
- Subjects
Aging ,medicine.medical_specialty ,Mechanotransduction ,Biophysics ,Osteoclasts ,Apoptosis ,Bone tissue ,Osteocytes ,Bone resorption ,Bone and Bones ,Bone remodeling ,Mechanobiology ,Osteogenesis ,Internal medicine ,Bone cell ,medicine ,Extracellular ,Animals ,Humans ,Bone Resorption ,Bone ,Osteoblasts ,Chemistry ,Osteocyte ,Cell biology ,Endocrinology ,medicine.anatomical_structure ,Load ,Collagen ,Stress, Mechanical ,Geriatrics and Gerontology ,Signal Transduction - Abstract
Bone is a tissue that dynamically adapts mass and architecture to the mechanical loads that occur in daily life in a world with gravity. Bone architecture and mass are influenced by the applied tension peak, whereas the bone formation rate is modulated by the stimulus frequency. In bone tissue, osteocytes govern the detection of mechanical afferents and their transformation into biochemical messages, therefore these cells can be considered a mechanosensor that directs osteogenesis to where it is most needed to increase bone strength. The stimulation of osteocytes occurs with several modalities: shear stress and stretch, extracellular pressure modifications, strains, variations of electric field in and around osteocytes lacunae. The osteocyte network, under physiological conditions, activates osteoclastogenesis and suppresses osteoblast function enhancing bone resorption and inhibiting bone formation. In the unloaded condition, the functions of the osteocyte network are augmented, whereas exercise could decrease inhibitory effects on bone mass by reducing both osteoclastogenesis and inhibition on osteoblast function.
- Published
- 2013
18. Differential characteristics of bone quality and bone turnover biochemical markers in patients with hip fragility fractures and hip osteoarthritis: results of a clinical pilot study
- Author
-
G Iolascon, Marina Brama, Umberto Sala, Silvia Migliaccio, Giuseppina Resmini, Stefania Maggi, Luca Dalle Carbonare, Nazzarena Malavolta, Rachele Fornari, Paola Siviero, Resmini, G, Migliaccio, S, Carbonare, Ld, Sala, U, Brama, M, Fornari, R, Maggi, S, Siviero, P, Malavolta, N, and Iolascon, Giovanni
- Subjects
musculoskeletal diseases ,Male ,Aging ,Bone density ,medicine.medical_treatment ,Urinary system ,Acid Phosphatase ,Dentistry ,Pilot Projects ,Osteoarthritis ,Prosthesis ,Bone resorption ,Collagen Type I ,Osteoarthritis, Hip ,Bone remodeling ,Bone Density ,medicine ,Humans ,Aged ,Aged, 80 and over ,Hyperparathyroidism ,Hip fracture ,business.industry ,Hip Fractures ,Tartrate-Resistant Acid Phosphatase ,Middle Aged ,medicine.disease ,Isoenzymes ,Parathyroid Hormone ,Case-Control Studies ,Calcium ,Female ,Bone Remodeling ,Hip Prosthesis ,Geriatrics and Gerontology ,business ,Peptides ,Biomarkers - Abstract
Background and aims: Bone density and quality alterations worsen the ability of osteoporotic bone to support prosthetic implants. The aim of our study was to evaluate potential differences in bone quality and bone turnover markers in aged individuals undergoing surgery for hip fragility fracture or hip osteoarthritis. Methods: Eighteen subjects with hip fragility fractures (Hip Fracture Group), 35 subjects with osteoarthritis of the hip (Hip Osteoarthritis Group) and 19 subjects with normal femoral bone mineral density (Control Group) were evaluated. Serum and urinary bone markers were assayed preoperatively in all surgical patients, and within 48 hours after fracture in the Hip Fracture, Osteoarthritis and Control groups. Histomorphometric analysis was performed on surgical samples. Results: A significant alteration in calcium and PTH serum levels with hyperparathyroidism was observed in the Hip Fracture Group compared with Hip Osteoarthritis and Control Groups. C-Terminal telopeptides of type I-collagen (CTx) and tartrate resistant-acid phosphatase (TRAP), markers of bone resorption, were increased in the Hip Fracture Group compared with both Osteoarthritis and Control Groups (CTx: p
- Published
- 2011
19. QUESTRIONNAIRE SURVEY TO VALIDATE AN EDUCATIONAL PROGRAM INTENDED FOR SURGEONS TO IMPROVE THE MANAGEMENT OF SEVERE OSTEOPOROSIS
- Author
-
Cerocchi, Irene, Resmini, Giuseppina, Antonio Capone, Iolascon, Giovanni, Nardi, Alfredo, Tarantino, Umberto, Cerocchi, I, Resmini, G, Capone, A, Iolascon, Giovanni, Nardi, A, and Tarantino, U.
- Subjects
Settore MED/33 - Malattie Apparato Locomotore
20. Evaluation of persistence and adherence to teriparatide treatment in patients affected by severe osteoporosis (PATT): A multicenter observational real life study
- Author
-
G Iolascon, M Frigato, Umberto Tarantino, I Cerocchi, Silvia Migliaccio, Di Pietro G, Francesca Gimigliano, R. Mulè, A. Buffa, Monica Celi, Giuseppina Resmini, Nazzarena Malavolta, Andrea Lenzi, A. Dormi, Rachele Fornari, Migliaccio, S, Resmini, G, Buffa, A, Fornari, R, Di Pietro, G, Cerocchi, I, Dormi, A, Gimigliano, Francesca, Mulè, R, Celi, M, Frigato, M, Lenzi, A, Tarantino, U, Iolascon, Giovanni, and Malavolta, N.
- Subjects
teriparatide ,Chronic condition ,medicine.medical_specialty ,business.industry ,Materials Science (miscellaneous) ,Osteoporosis ,adherence ,osteoporosis ,persistence ,pharmacological treatment ,Osteoporosi ,medicine.disease ,Regimen ,Migraine ,Internal medicine ,Physical therapy ,medicine ,Teriparatide ,Original Article ,Observational study ,Adverse effect ,business ,Depression (differential diagnoses) ,medicine.drug - Abstract
Introduction. Osteoporosis is a chronic condition leading to an increased risk of developing fractures, with high morbidity and mortality in aging population. Efficacy of anti-osteoporotic treatment is based on drug potency but also on compliance and persistence to treatment regimen, which is very low, as already described for other diseases. Teriparatide (TPTD) is the first anabolic agent developed for the treatment of osteoporosis. Since it appears that persistence to Teriparatide declines over time, aim of this pilot multicenter observational study was to evaluate persistence and adherence to TPTD (20 μg daily injection regimen for 18 months) treatment (PATT) in patients affected by severe osteoporosis in an every day clinical practice. Methods. Patients affected by severe osteoporosis were selected among those who referred to 5 different specialized centers for osteoporosis in North, Center and South of Italy. A sample of 475 women with severe postmenopausal osteoporosis treated with TPTD in accordance to the Italian osteoporosis guidelines was included. At the beginning of TPTD treatment patients were instructed on the use of the device by the referring specialist of the center, a resident fellow or a nurse. Bone biochemical markers were evaluated the same morning and after 1, 3, 6, 12 and 18 months. Patients were visited at time 0 and after 6, 12 and 18 months for clinical follow up. Results. The results included observations of 441/475 patients (98% women) who completed the 18 months treatment; mean age for women was 73±8 and for men 65±9. After 6 months of TPTD treatment persistence was of 89,79%, 87,75% after 12 months and 86,85% after 18 months. Adherence was of 100% at 6,12 and 18 months. Total dropouts were 13,15% (71/441), which was usually higher within the first 6 months of TPTD treatment. Most common adverse events (arthralgies 2,7%, dizziness 1,8%, migraine 1,8%, depression 1,6%, hypertension 1,1%) were reported in 62/441 patients (14%) of patients, but were not reason for stopping treatment. Conclusions. The persistence and adherence to TPTD treatment obtained in this multicenter observational real life study was very high as compared to studies performed by others. These encouraging results suggest that different key factors such quality of information, frequency of visits, motivations given to patients, opportunity to call the doctor might play a pivotal role in the high persistence and adherence to TPTD treatment obtained in our study and need to be carefully considered before prescribing chronic anti-osteoporotic therapy
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.